For fiscal 2026 (ended Jun 30, 2026), Alterity Therapeutics Limited reported A$1.72M of revenue and -A$23.40M of net income. Figures are in AUD, the currency of its SEC filings.
ATHE revenue was A$1.72M for fiscal 2026 (ended Jun 30, 2026), down 78.8% from fiscal 2025. Compound annual growth was -17.6% over 5 years and -10.0% over 10 years. It rose in 6 of the last 10 fiscal years.
ATHE net income was -A$23.40M for fiscal 2026 (ended Jun 30, 2026), compared with -A$12.15M in fiscal 2025.
ATHE diluted EPS was -A$0.19 for fiscal 2025 (ended Jun 30, 2025).
ATHE free cash flow was -A$22.52M for fiscal 2026 (ended Jun 30, 2026), compared with -A$11.45M in fiscal 2025.
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | A$1.72M | A$8.09M | A$4.29M | A$3.93M | A$5.13M | A$4.51M | A$139.8K | A$5.06M | A$3.33M | A$3.16M |
| Research and development | A$17.63M | A$14.40M | A$18.64M | A$13.20M | A$14.75M | A$12.28M | A$10.10M | A$12.98M | A$6.70M | A$5.70M |
| Selling, general and admin | A$10.53M | A$5.48M | A$4.76M | A$5.06M | A$5.51M | A$6.94M | A$3.45M | A$4.31M | A$4.34M | A$3.97M |
| Interest expense | - | A$6.2K | A$7.2K | A$4.6K | A$2.3K | A$1.3K | A$3.9K | - | - | - |
| Pre-tax income | -A$23.29M | -A$12.08M | -A$19.08M | -A$13.70M | -A$12.78M | -A$15.31M | -A$13.46M | -A$12.34M | -A$8.27M | -A$7.54M |
| Income tax | A$113.5K | A$68.1K | A$46.1K | A$104.5K | A$70.0K | - | - | A$0 | A$0 | A$0 |
| Net income | -A$23.40M | -A$12.15M | -A$19.12M | -A$13.81M | -A$12.85M | A$15.31M | A$13.46M | A$12.34M | -A$8.27M | -A$7.54M |
| EPS, basic | -A$11.12 | -A$9.50 | -A$26.20 | -A$0.57 | -A$0.53 | -A$0.90 | -A$1.50 | - | - | - |
| EPS, diluted | - | -A$0.19 | -A$0.52 | -A$0.57 | -A$0.53 | -A$0.90 | -A$1.50 | -A$2.00 | - | - |
| Diluted shares | 210.5M | 127.9M | 73.0M | 2.43B | 2.41B | 1.70B | 894.9M | 615.8M | 533.9M | 533.9M |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | A$37.32M | A$33.16M | A$12.64M | A$15.77M | A$34.81M | A$28.12M | A$9.20M | A$14.40M | A$15.24M | A$21.88M |
| Receivables | A$7.70M | A$3.94M | A$4.04M | A$8.67M | A$4.73M | A$4.28M | A$61.3K | A$4.83M | A$3.15M | A$3.04M |
| Current assets | A$45.83M | A$45.87M | A$19.04M | A$27.05M | A$41.14M | A$33.49M | A$9.84M | A$19.86M | A$18.65M | A$25.25M |
| Total assets | A$46.02M | A$46.03M | A$19.22M | A$27.32M | A$41.36M | A$33.59M | A$9.91M | A$19.91M | A$18.73M | A$25.28M |
| Current liabilities | A$3.16M | A$3.53M | A$5.37M | A$4.38M | A$5.82M | A$3.07M | A$2.71M | A$3.32M | A$2.64M | A$1.59M |
| Total liabilities | A$3.29M | A$3.62M | A$5.43M | A$4.50M | A$5.89M | A$3.12M | A$2.76M | A$3.36M | A$2.64M | A$1.59M |
| Shareholders' equity | A$42.72M | A$42.40M | A$13.80M | A$22.81M | A$35.47M | A$30.47M | A$7.15M | A$16.55M | A$16.08M | A$23.69M |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -A$22.52M | -A$11.45M | -A$12.61M | -A$20.04M | -A$12.34M | -A$17.33M | -A$9.43M | -A$13.95M | -A$6.25M | -A$5.87M |
| Capital expenditures | A$0 | A$0 | A$5.7K | A$7.3K | A$89.1K | A$10.5K | A$16.7K | A$7.0K | A$62.4K | A$27.9K |
| Free cash flow | -A$22.52M | -A$11.45M | -A$12.61M | -A$20.04M | -A$12.43M | -A$17.34M | -A$9.45M | -A$13.96M | -A$6.31M | -A$5.89M |
| Investing cash flow | - | -A$7.50M | -A$5.7K | -A$36.5K | -A$89.1K | -A$10.5K | -A$16.7K | -A$7.0K | -A$18.4K | -A$27.9K |
| Financing cash flow | A$19.13M | A$39.67M | A$9.22M | A$124.3K | A$16.30M | A$36.69M | A$3.98M | A$12.72M | -A$107.7K | -A$159.6K |
| Stock-based compensation | A$4.49M | A$979.9K | A$882.0K | A$966.6K | A$1.51M | - | - | - | - | - |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -78.8% | 88.6% | 9.0% | -23.3% | 13.8% | 3122.0% | -97.2% | 52.1% | 5.4% | -35.6% |
| Net income growth, YoY | - | - | - | - | - | 13.8% | 9.1% | - | - | - |
| Net margin | -1363.2% | -150.2% | -446.0% | -351.1% | -250.6% | 339.8% | 9622.6% | 243.8% | -248.4% | -239.0% |
| Free cash flow margin | -1312.0% | -141.6% | -294.1% | -509.6% | -242.4% | -384.8% | -6755.9% | -275.9% | -189.6% | -186.8% |
| Return on equity | -54.8% | -28.6% | -138.6% | -60.5% | -36.2% | 50.2% | 188.2% | 74.5% | -51.4% | -31.8% |
| Return on assets | -50.9% | -26.4% | -99.5% | -50.5% | -31.1% | 45.6% | 135.8% | 62.0% | -44.1% | -29.8% |
| Current ratio | 14.52 | 12.98 | 3.54 | 6.17 | 7.07 | 10.92 | 3.62 | 5.98 | 7.06 | 15.88 |
Source: XBRL data Alterity Therapeutics Limited files with the SEC, latest filing dated Aug 28, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ATHE | A$1.72M | -78.8% | -A$23.40M | -1363.2% | $44.2M |
| ANVS | $0 | - | -$49.52M | - | $38.6M |
| PRTA | $52.73M | +347.4% | -$23.96M | -45.4% | $450.9M |
| ACIU | CHF 3.57M | -86.9% | -CHF 70.45M | -1971.6% | $248.3M |
| AVXL | - | - | -$13.02M | - | $113.1M |
| DNLI | $21.38M | - | -$314.42M | -1470.5% | $3.26B |